ArticleFrontiers in artificial intelligence2025
Leveraging psychedelic neuroscience to boost human creativity using artificial intelligence.
Article in Frontiers in artificial intelligence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychedelics, such as LSD and psilocybin, disrupt entrenched cognitive patterns by facilitating novel insights and new associations. This paper considers how AI can potentially mimic these psychedelic-induced cognitive disruptions to augment and enhance human creativity. Psychedelics likely enhance creativity by altering brain function, notably the activity of the Default Mode Network, which leads to changes in cognition. Psychologically, they may reduce latent inhibition, increase divergent thinking, and promote implicit learning. Similarly, AI systems can replicate these creative enhancements by introducing novel associations, reframing familiar information, and facilitating unconscious cognitive shifts. The risks associated with AI use are also compared to psychedelics, including dependency, ethical concerns, and homogenization of outputs due to bias. Integrating the cognitive mechanisms activated by psychedelics into AI design provides promising pathways for creativity enhancement. Carefully designed AI could act as a cognitive catalyst, fostering innovative thought processes and adaptive problem-solving while addressing identified ethical and practical concerns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.